Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia

NCT04801797 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04801797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04801797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 20, 2021
Completion date
January 1, 2028
Enrollment
172 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia